Congenica aims to turn data into information
Sequencing data is all well and good, but what does it mean?
Oxford Nanopore, the disruptive unicorn gunning for Illumina
Can the company's $1.5bn valuation be justified when last year it took just $23.5m in orders?
Smaller medtechs soar in ’17 but could now be too expensive
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.